GlaxoSmithKline plc (NYSE:GSK) Shares Sold by Keybank National Association OH

Keybank National Association OH reduced its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 7.7% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 60,920 shares of the pharmaceutical company’s stock after selling 5,109 shares during the quarter. Keybank National Association OH’s holdings in GlaxoSmithKline were worth $2,600,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in GSK. Jane Street Group LLC increased its position in GlaxoSmithKline by 7,574.0% during the 2nd quarter. Jane Street Group LLC now owns 1,816,424 shares of the pharmaceutical company’s stock valued at $72,693,000 after buying an additional 1,792,754 shares in the last quarter. Fisher Asset Management LLC increased its position in GlaxoSmithKline by 10.2% during the 3rd quarter. Fisher Asset Management LLC now owns 15,267,588 shares of the pharmaceutical company’s stock valued at $651,621,000 after buying an additional 1,412,368 shares in the last quarter. Renaissance Technologies LLC increased its position in GlaxoSmithKline by 6.9% during the 2nd quarter. Renaissance Technologies LLC now owns 15,261,781 shares of the pharmaceutical company’s stock valued at $610,776,000 after buying an additional 989,181 shares in the last quarter. Point72 Asset Management L.P. increased its position in GlaxoSmithKline by 362.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,105,172 shares of the pharmaceutical company’s stock valued at $44,229,000 after buying an additional 866,015 shares in the last quarter. Finally, Invesco Ltd. increased its position in GlaxoSmithKline by 502.4% during the 2nd quarter. Invesco Ltd. now owns 644,331 shares of the pharmaceutical company’s stock valued at $25,786,000 after buying an additional 537,370 shares in the last quarter. 11.19% of the stock is currently owned by institutional investors.

Shares of GSK stock traded up $0.21 during mid-day trading on Friday, reaching $44.42. The stock had a trading volume of 1,985,586 shares, compared to its average volume of 2,550,711. The business’s fifty day moving average is $42.96 and its 200-day moving average is $41.12. The company has a current ratio of 0.82, a quick ratio of 0.56 and a debt-to-equity ratio of 1.38. The firm has a market cap of $110.42 billion, a price-to-earnings ratio of 14.06, a PEG ratio of 3.03 and a beta of 0.70. GlaxoSmithKline plc has a 1-year low of $36.41 and a 1-year high of $46.01.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, October 30th. The pharmaceutical company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.10. The business had revenue of $11.57 billion for the quarter, compared to analyst estimates of $11.34 billion. GlaxoSmithKline had a return on equity of 92.73% and a net margin of 13.76%. On average, analysts forecast that GlaxoSmithKline plc will post 3.08 earnings per share for the current year.

Several brokerages recently issued reports on GSK. Jefferies Financial Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, August 29th. Goldman Sachs Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research report on Wednesday, October 30th. Citigroup reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday. ValuEngine raised GlaxoSmithKline from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Finally, UBS Group reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $41.79.

In other news, Director Plc Glaxosmithkline acquired 177,777 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average cost of $45.00 per share, with a total value of $7,999,965.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.00% of the stock is currently owned by corporate insiders.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Story: Options Trading – Understanding Strike Price

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.